Sign in

CIK 0001231457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

GENELUX Corp

Sign in to watch
Ticker
GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
805-267-9889
Business address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$155,693
in 6 filings

Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 71 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-08-01 Thomas John Director Grant or award · Stock Option Right to Buy) +50,469 50,469
2024-08-01 Smither John W Director Grant or award +39,541 52,711
2024-08-01 Smither John W Director Grant or award · Stock Option Right to Buy) +50,469 50,469
2024-06-24 Yu Yong VP, Clinical Trial Operations Sale −6,849 $2.12 $15K 10,869
2024-06-24 Ryder Sean General Counsel Sale −5,496 $2.12 $12K 19,388
2024-06-24 Jewett Caroline Head of Quality Sale −4,961 $2.12 $11K 16,174
2024-05-29 Tyree James L Director Purchase +6,250 9,710
2024-05-29 Tyree James L Director Purchase · Common Stock Warrant (Right to Buy) +6,250 6,250
2024-05-29 Smither John W Director Purchase +6,250 13,170
2024-05-29 Smither John W Director Purchase · Common Stock Warrant (Right to Buy) +6,250 6,250
2024-05-29 Thomas John Director Purchase +2,500 465,960
2024-05-29 Thomas John Director Purchase · Common Stock Warrant (Right to Buy) +2,500 2,500
2024-05-29 Mirabelli Mary Director Purchase +8,000 12,460
2024-05-29 Mirabelli Mary Director Purchase · Common Stock Warrant (Right to Buy) +8,000 8,000
2024-05-29 Yu Yong VP, Clinical Trial Operations Purchase +2,500 2,500
2024-05-29 Yu Yong VP, Clinical Trial Operations Purchase · Common Stock Warrant (Right to Buy) +2,500 2,500
2024-03-14 Zindrick Thomas President and CEO Grant or award +26,264 50,207
2024-03-14 Zak Lourie S. Chief Financial Officer Grant or award +3,852 38,428
2024-03-14 Smalling Ralph Head of Regulatory Grant or award +2,107 18,144
2024-03-14 Cappello Joseph VP, Pharmaceutical Development Grant or award +11,557 20,953

Page 8 of 9 · 170 trades